Parapneumonic EffussionVATs-PPENCT07188714
Video-assisted Thoracoscopic Surgery (VATS) Has Revolutionised Management of Complicated PPE, Our Study to Determine VATS Decortication Technique is Needed, Compared to VATS Debridement in PPE, Also RAPID Score and Pleural US Parameters Can Predict Which VATS Procedure is Needed.
A study testing VATs decortication and VATs debridement in people with Parapneumonic Effussion, run by Assiut University at 1 site in Egypt.
Trial summary
Video-assisted thoracoscopic surgery (VATS) has revolutionised management of complicated parapneumonic effusion ( PPE). So our study is prospective cohort study will be conducted at Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals Aims: to determine the frequency of which VATS… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parapneumonic Effussion
- What is being tested?
- VATs decortication and VATs debridement
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 95 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Oct 2025to 10 Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyser), low glucose level (⩽3 mmol/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection [6].
- Failed resolution of parapneumonic effusion:
- Given a patient-to-patient variability in response to medical treatment, therapeutic pleurocentesis and ICT drainage, a MDT involving consultant cardiothoracic surgeons and consultant pulmonologist are to discuss enrolled cases individually , reach consensus, and declare failure of medical treatment or ICT drainage and need for surgical intervention , based on combination of clinical , laboratory, and radiological parameters (persistence of fever. Elevated Wbcs, respiratory symptoms, pleural fluid loculi inaccessible by ICT, lung entrapment despite complete drainage of fluid or large bronchopleural fistula
Who cannot join
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the aetiology.
- Exudative pleural effusion due to medical conditions other than pneumonia (suspected or proven Para malignant effusion, associated pulmonary embolism, autoimmune, pancreatic or oesophageal disease, gynaecological disorder, and drug-induced pleural effusion).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Assiut university- Faculty of medicine
Asyut, Assiut Governate, 71111
Assiut university hospital Asiut
Hamed Farrag Qenawy, master degree
About this study
Official title: Preoperative Prediction of VATS Strategy in Parapneumonic Effusion
Video-assisted thoracoscopic surgery (VATS) has revolutionised management of complicated parapneumonic effusion ( PPE). So our study is prospective cohort study will be conducted at Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals
- Aims: to determine the frequency of which VATS technique is needed (decortication versus debridement ) and to verify whether baseline RAPID score and pleural US parameters can predict which VATS procedure (decortication vs. debridement) in patients with complicated PPE will need, upon intra-operative exploration to compare the time to ICT removal after lung expansion and length of hospital stay in patients with PPE undergoing VATS via either debridement or decortication approach .
- Subjects: All patients with PPE presenting with suggestive symptoms,signs or radiological studies which display compatible patterns of PPE:
Read more
- Inclusion criteria:
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyser), low glucose level (⩽3 mmol/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection .
- Failed resolution of parapneumonic effusion.
- Exclusion criteria:
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the etiology.
- Exudative pleural effusion due to medical conditions other than pneumonia .
- Sample size was calculated using Epi-info software version 7.2.5.0. The total sample size needed to detect such an estimate with 95% confidence level and 10% margin of error will be 95 patients
- Research outcome measures:
- Primary (main):
- Number of the patients who will receive either VATS technique (and the respective percentage in relation to the total patients)
- Preoperative Adjusted RAPID score and US findings (fluid volume, echogenicity, pleural thickening, consolidation and other incidental findings).
- Assessment the radiological signs of lung expansion
CXR/US scores:
- Failure: Chest X-ray scoring 0 and chest US scoring 0.
- Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1.
- Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
- Secondary (subsidiary):
- Time to ICT removal (days). ICT tube will be removed based on the MDT joint decision according to the patients' individual course. Tube removal is contemplated upon clinical resolution, complete fluid drainage, full lung expansion and absence of pleural air in CXR, in the absence of air leak, chest ultrasound to assess if there is residual pleural effusion.
- Length of Hospital Stay (days)
- Status at discharge (ICT removed or not)
- Patients reported outcomes:
- Postoperative pain (VAS) at discharge time
- Resumption of usual activities (self-care routine with assistance - unassisted self-care- other activities indoors- independent indoors and outdoors activities) by attending the patient to the hospital within 30 days post discharge.
- Mortality rate within 30 days postoperative.
Read the detailed description
- Type of the study: Prospective Cohort Study.
- Study Group: VATS debridement versus VATS decortication.
- Study Setting: Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals.
- Study subjects:
All patients with PPE presenting with suggestive symptoms (acute onset fever, cough, expectoration ± pleuritic chest pain or hemoptysis), signs (fever, increased TVF, Bronchial breath sound, localized crepitation) or radiological studies (CXR and pleural US ±CT Chest) which display compatible patterns (semihomgenous opacity with blunting of the costophrenic angle, homogenous opacity suggestive loculated effusion, air bronchogram):
- Inclusion criteria:
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyzer), low glucose level (⩽3 mole/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection .
- Failed resolution of parapneumonic effusion:
- Exclusion criteria:
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the aetiology.
- Exudative pleural effusion due to medical conditions other than pneumonia (suspected or proven Para malignant effusion, associated pulmonary embolism, autoimmune, pancreatic or esophageal disease, gynecological disorder, and drug-induced pleural effusion).
- Sample Size Calculation: The sample size was calculated using Epi-info software version 7.2.5.0 . The total sample size needed to detect such an estimate with 95% confidence level and 10% margin of error will be 95 patients. -Study tools :all patients will be subjected to:
- Demographic data (age, gender) and clinical data (including comorbidities -such as underlying COPD, D.M, HTN, cardiac, hepatic, or renal diseases, immunodeficiency or administration of immunosuppressive therapy- symptoms and their duration, time to admission, time before ICT insertion and duration of antibiotics used) will be collected and documented.
- Laboratory testing:
- Samples for baseline Complete blood count (CBC) with differential count, renal (serum urea and creatinine) and liver function tests (total protein, ALT, AST, albumin), coagulation profile (PT, PC, INR), LDH,ESR, and CRP will be , fasting and 2 hour postprandial blood sugar level will be collected, analyzed and their results will be documented.
- Biochemical and microbial analysis of the pleural effusion will be conducted. This will include pleural pH, glucose level , LDH, total protein and albumin, culture and sensitivity for bacteria, as well as direct smear for A.F.B./Gene Expert (if pleural tuberculosis is suspected) by thoracentesis using ultrasound to guide selection of an adequate length needle. At least 10 mm depth to do diagnostic thoracentesis .
- Radiological studies before and after intervention:
- Chest X ray (CXR) PA/Lateral film. ii) Contrast-enhanced CT chest if deemed necessary by the MDT. Data about extent of the effusion, presence of loculi or pleural thickening, as well as the underlying lesions (pneumonia, mass, nodules) will be documented iii) Chest US:
- The device: Curvilinear US probe (Samsung Madison CO-LTD.42 .Teheran-ro-108-gil.Gangnam-gu. Seoul. Korea) that generates a frequency range of 2-5 MHz which has great penetration but lower resolution .
- Examination protocol: Patients are to be examined in the supine and sitting positions, arms raised and hands placed at the back of the head to expand the intercostal spaces and rotate the scapula outward. Examination will be performed systematically through the intercostal spaces in six vertical lines which are mid clavicular, anterior axillary, mid axillary, posterior axillary, mid scapular and paravertebral .and will cover 8 zones in each lung side (supra-mammary, mammary ,infra-mammary, upper axillary ,lower axillary ,supra-scapular ,inter-scapular , infrascapular ) . Sonographic Findings (include fluid volume, fluid echogenicity, pleural thickening, findings demonstrating the underlying pneumonia (hyperechoic comma-shape artifacts representing air bronchogram/C profile), other incidental findings (nodules, hypoechoic lesions).
- Fluid volume: First, the maximal inter-pleural distance at posterior-lateral Alveolar and pleural syndrome (PLAPS) point is measured during expiration in a semi-recumbent position. Then, the volume of the pleural fluid will be calculated using Balik's Formula where . V(ml)= 20 x Distance (mm)
- Echogenicity: Effusion is defined as anechoic when it is echo-free, as complex non-septate when echogenic material is inside the effusion, and as complex septate when floating fibrin strands or septa are found inside the effusions.
- Assessment of Mortality and Morbidity Risks: Adjusted RAPID score is a simple and easily calculated score that assesses mortality risk for patients with pleural infections. The score entails 8 parameters (Renal (urea), age, fluid purulence, infection source, dietary (albumin), diabetes mellitus, renal insufficiency (dialysis), immunosuppression are assigned . The total adjusted RAPID score (0-10 points) represents the sum of the points assigned to the 8 parameters together, on the basis of which the patient's risk for 90 days mortality is determined .
- Assessment of Fitness for Anesthesia and Surgery: ASA score (American Society of Anesthesiologists Physical Status ) It is a standardized way to assess a patient's overall health and fitness before surgery. It uses a scale of I to VI, with I being a healthy patient and VI being a deceased organ donor. An "E" is added to the number if the procedure is an emergency. According to age, diseases severity, associated comorbidities, the anaestheology team assign the patient into one of six classes that define the patient's fitness status in a descending rank.
- Anesthesia: The type of the anesthesia that will be administrated to the patient (general or regional) will be documented, as well as the drugs used during anesthesia as (inhalational anesthetics like sevoflurane, and intravenous agents like Propofol and remifentanil). 7- VATS technique:
- Materials : The following equipment is used to perform a VATS: 1-5 or 10 mm high-resolution fiber-optic thoracoscopy with a 0° or 30° lens 2-A light source with a cable 3-Video monitors 4-Thoracoscopic instruments (scissors, hook or straight-blade cautery, biopsy forceps, grasper, and dissector) 5-Endoscopic stapler if resection is planned 6-Trocars 7-Thoracotomy tray (to convert to open procedure if needed) 8-Chest tubes and drainage devices 9-Sterile gloves, gowns, and drapes 10-Double-lumen endotracheal tube
- Procedure steps :
- The whole series will be operated upon under general anesthesia, using a double-lumen tube for selective ventilation.
- Patients will be placed in a decubitus position on an operating table with a standby set of thoracotomy instruments ready in case of conversion.
- A small incision (3-5 cm) is to be made in the 5th intercostal space anterior axillary line then dissection of the subcutaneous tissue and muscles was done. Port inserted with A 30-degree lens (Karl-Storz) in a 10-mm sheath thoracoscopy was introduced at the top of the incision.
- After opening the port site, a gentle digital palpation to push the lung away from chest wall and create a space where camera can be introduced. Using the suction tip or a sponge on a stick afterward to further continue the dissection under vision .
- Debridement technique : The aim of debridement (removal of pus, debris, granulation tissue) is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations. Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion.
- Decortication technique :
- For cases with lung entrapment by thick visceral peel or clotted hemothorax, irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura.
- A long thoracoscopy instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniport procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.
- After performing decortication, a warmed saline solution for flushing again inside the chest cavity through a 50-cc syringe for irrigation then suctioned after anesthetist start to ventilate this side and air leak was checked. -Decortication will be considered completed when near full lung expansion takes place with anesthetist inflating the lung with pressure between 30 and 35 mmHg. Failure to get the whole lung inflation needs a revision of the decortication and either continuing VATS or converting to open surgery depending on the comfort of the operator. 8-Post-Operative Care:
- ICT insertion :
- Tools: 2 hemostats, nylon suture (0 or 0-1), scalpel size (11blade), suction apparatus, water seal drainage, chest tube ranges from 28-32 French for Para pneumonic effusion.
- Chest tube will be inserted from the same port site then secured by sutures and other ports closed in standard fashion, so termination the surgical procedure and start recovery from anesthesia.
- Recovery from anesthesia: Awaken a patient after general anesthesia by gradually reduce and eventually stop the anesthetic medications. The patient will then be monitored closely as they naturally wake up and regain consciousness, breathing on their own.
- Site of admission: All Patients will be sent to the ward or the intermediate care unit, as a part of the institution's protocol.
- Analgesia: According to pain ladder score : The original ladder mainly consisted of three steps: 1-First Step: Mild pain: non-opioid analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen with or without adjuvants. 2-Second Step: Moderate pain: weak opioids (hydrocodone, codeine, tramadol) with or without non-opioid analgesics and with or without adjuvants. 3-Third Step: Severe and persistent pain: potent opioids (morphine, methadone, fentanyl, oxycodone, buprenorphine, tapentadol, hydromorphone, oxymorphone) with or without non-opioid analgesics, and with or without adjuvant. Adjuvants, also called co-analgesics, include antidepressants, including tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine, anticonvulsants like gabapentin and pregabalin, topical anesthetics (e.g., lidocaine patch), topical therapies (e.g., capsaicin), corticosteroids, bisphosphonates, and cannabinoids .
- Early mobilization and physiotherapy will be encouraged in all patients until discharge. 9-Follow Up protocol postoperative: i) Amount of drained fluid daily in cc, color (serous, pus, blood or serosanguinous) (pre-operative and post-operative). ii) CXR and Chest US in day prior to surgery and 1 day postoperative then at discharge :
- Chest X-ray is to be scored into: No change in the first X-ray before VATS takes score ( 0) Less than 1/3 improvement/lung expansion takes score(1). Improvement between 1/3 and 2/3 takes score (2). More than 2/3 improvement without complete clearance of effusion takes score(3). Complete radiological clearance/complete lung expansion takes score(4)
- Chest US findings is to be scored into: No change takes score(0). Dissolution of adhesions in some regions takes score(1). Dissolution of adhesions in all regions with residual pleural affection takes score(2). Total adhesion dissolution without residual pleural lesion takes score(3). iii) Presence of air leak at discharge. iv) Visual analogue Sore (VAS): It is a scale from 0-10 cm with 0 value on the left side representing maximum comfort and 10 representing maximum discomfort on the right side will be assessed at in day prior to surgery and 1 day postoperative then at discharge . -Research outcome measures:
<!-- -->
- Primary (main):
- Number of the patients who will receive either VATS technique (and the respective percentage in relation to the total patients)
- Preoperative Adjusted RAPID score and US findings (fluid volume, echogenicity, pleural thickening, consolidation and other incidental findings).
- Assessment the radiological signs of lung expansion: CXR/US scores: -Failure: Chest X-ray scoring 0 and chest US scoring 0.
- Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1.
- Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
- Secondary (subsidiary):
- Time to ICT removal (days): ICT tube will be removed based on the MDT joint decision according to the patients' individual course. Tube removal is contemplated upon clinical resolution, complete fluid drainage, full lung expansion and absence of pleural air in CXR, in the absence of air leak, chest ultrasound to assess if there is residual pleural effusion.
- Length of Hospital Stay (days)
- Status at discharge (ICT removed or not)
- Patients reported outcomes:
- Postoperative pain (VAS) at discharge time
- Mobility (bed bound- need for assistance as wheelchair or help of relatives to move -freely and independently ambulatory) by attending the patient to the hospital within 30 days post discharge.
- Resumption of usual activities (self-care routine with assistance - unassisted self-care- other activities indoors- independent indoors and outdoors activities) by attending the patient to the hospital within 30 days post discharge.
- Mortality rate within 30 days postoperative, documentation of the cause of death will be attempted.
- Complication : minor as bleeding, wound infection, surgical emphysema, postoperative blood transfusion or major as worsening of pneumonia, sepsis, persistent air leak, need to re-exploration.
- Conditions
- Parapneumonic Effussion
- Being tested
- VATs decortication, VATs debridement
- Keywords
- VATs in Parapneumonic effussion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VATs decorticationProcedure or surgery
A long thoracoscopic instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniportal procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.
Irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura.
VATs debridementProcedure or surgery
Removal of pus, debris, granulation tissue is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations.
Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion
| Study group | Role | What they receive |
|---|---|---|
| decortication arm | Active comparator | patients with PPE complicated by stage 3 empyema will underwent decortication technique Receives: Procedure: VATs decortication |
| debridement arm | Active comparator | patients with PPE complicated by stage 2 empyema will underwent debridment technique Receives: Procedure: VATs debridement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment the radiological signs of lung expansion
CXR/US scores:
- Failure: Chest X-ray scoring 0 and chest US scoring 0.
- Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1.
- Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
Measured: perioperative
Preoperative Adjusted RAPID score and US findings
Preoperative Adjusted RAPID score which determine what is the technique will be used ( decortication or debridement ) as shown :
Adjusted RAPID score is a simple and easily calculated score that assesses mortality risk for patients with pleural infections. The score entails 8 parameters (Renal (urea), age, fluid purulence, infection source, dietary (albumin), diabetes mellitus, renal insufficiency (dialysis), immunosuppression are assigned as seen in Figure(1). The total adjusted RAPID score (0-10 points) represents the sum of the points assigned to the 8 parameters together, on the basis of which the patient's risk for 90 days mortality is determined .
Risk categories :
score 0-2 low risk score 3-4 intermediate risk score 5-7 high risk score 8-10 very high risk
Measured: the baseline
Secondary outcomes (1)
Time to ICT removal (days)
ICT tube will be removed based on the MDT joint decision according to the patients' individual course. Tube removal is contemplated upon clinical resolution, complete fluid drainage, full lung expansion and absence of pleural air in CXR, in the absence of air leak, chest ultrasound to assess if there is residual pleural effusion.
Measured: through study completion, an average of 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2025
- Study start25 Oct 2025 (estimated)
- Primary completion10 Sep 2027 (estimated)
- Study completion10 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Parapneumonic EffussionStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Patients with complicated pleural infections, who don't improve after antibiotics and drainage of fluid by chest tube, will undergo surgery. The procedure may be debridement, where the surgeon only removes pus and debris, wash the thoracic cavity with saline and inserts chest tube. If the surgeon finds it necessary, he will proceed to decortication, where he also peels-off the thick infected pleura covering the lung to allow lung regain its size and help improvement. Follow up will include, clinical assessment, laboratory tests, periodic CXR to decide whether it's appropriate to remove the chest tube or not
- Masking
- None (open label)
- Enrolment
- 95 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hamed Farrag Qenawy, Assiut University
- Investigators
- Sara Mohamed Hashem, MD, Study chair, Assiut Medical SchoolHend Mohamed Sayed, MD, Study chair, Assiut Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07188714
- Sponsor's protocol ID
- VATs,Assiut University 1
- Acronym
- VATs-PPE
- Status last verified
- Sep 2025
- First submitted
- 3 Sep 2025
- Last updated
- 23 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Bernstein WK, Deshpande S. Preoperative evaluation for thoracic surgery. Semin Cardiothorac Vasc Anesth. 2008 Jun;12(2):109-21. doi: 10.1177/1089253208319868.
PubMed 18635562Chambers A, Routledge T, Dunning J, Scarci M. Is video-assisted thoracoscopic surgical decortication superior to open surgery in the management of adults with primary empyema? Interact Cardiovasc Thorac Surg. 2010 Aug;11(2):171-7. doi: 10.1510/icvts.2010.240408. Epub 2010 May 3.
PubMed 20439299Towe CW, Carr SR, Donahue JM, Burrows WM, Perry Y, Kim S, Kosinski A, Linden PA. Morbidity and 30-day mortality after decortication for parapneumonic empyema and pleural effusion among patients in the Society of Thoracic Surgeons' General Thoracic Surgery Database. J Thorac Cardiovasc Surg. 2019 Mar;157(3):1288-1297.e4. doi: 10.1016/j.jtcvs.2018.10.157. Epub 2018 Nov 28.
PubMed 33198004Dean NC, Griffith PP, Sorensen JS, McCauley L, Jones BE, Lee YC. Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia. Chest. 2016 Jun;149(6):1509-15. doi: 10.1016/j.chest.2015.12.027. Epub 2016 Jan 16.
PubMed 26836918
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Preoperative Prediction of VATS Strategy in Parapneumonic Effusion
- ClinicalTrials.gov ID
- NCT07188714
- Acronym / sponsor ID
- VATs-PPE / VATs,Assiut University 1
- Conditions
- Parapneumonic Effussion
- Keywords
- VATs in Parapneumonic effussion
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 95 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 25 Oct 2025 (estimated)
- Primary completion
- 10 Sep 2027 (estimated)
- Study completion
- 10 Feb 2028 (estimated)
- First posted
- 23 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Video-assisted thoracoscopic surgery (VATS) has revolutionised management of complicated parapneumonic effusion ( PPE). So our study is prospective cohort study will be conducted at Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals
- Aims: to determine the frequency of which VATS technique is needed (decortication versus debridement ) and to verify whether baseline RAPID score and pleural US parameters can predict which VATS procedure (decortication vs. debridement) in patients with complicated PPE will need, upon intra-operative exploration to compare the time to ICT removal after lung expansion and length of hospital stay in patients with PPE undergoing VATS via either debridement or decortication approach .
- Subjects: All patients with PPE presenting with suggestive symptoms,signs or radiological studies which display compatible patterns of PPE:
- Inclusion criteria:
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyser), low glucose level (⩽3 mmol/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection .
- Failed resolution of parapneumonic effusion.
- Exclusion criteria:
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the etiology.
- Exudative pleural effusion due to medical conditions other than pneumonia .
- Sample size was calculated using Epi-info software version 7.2.5.0. The total sample size needed to detect such an estimate with 95% confidence level and 10% margin of error will be 95 patients
- Research outcome measures:
- Primary (main):
- Number of the patients who will receive either VATS technique (and the respective percentage in relation to the total patients)
- Preoperative Adjusted RAPID score and US findings (fluid volume, echogenicity, pleural thickening, consolidation and other incidental findings).
- Assessment the radiological signs of lung expansion
CXR/US scores:
- Failure: Chest X-ray scoring 0 and chest US scoring 0.
- Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1.
- Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
- Secondary (subsidiary):
- Time to ICT removal (days). ICT tube will be removed based on the MDT joint decision according to the patients' individual course. Tube removal is contemplated upon clinical resolution, complete fluid drainage, full lung expansion and absence of pleural air in CXR, in the absence of air leak, chest ultrasound to assess if there is residual pleural effusion.
- Length of Hospital Stay (days)
- Status at discharge (ICT removed or not)
- Patients reported outcomes:
- Postoperative pain (VAS) at discharge time
- Resumption of usual activities (self-care routine with assistance - unassisted self-care- other activities indoors- independent indoors and outdoors activities) by attending the patient to the hospital within 30 days post discharge.
- Mortality rate within 30 days postoperative.
Detailed description
- Type of the study: Prospective Cohort Study.
- Study Group: VATS debridement versus VATS decortication.
- Study Setting: Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals.
- Study subjects:
All patients with PPE presenting with suggestive symptoms (acute onset fever, cough, expectoration ± pleuritic chest pain or hemoptysis), signs (fever, increased TVF, Bronchial breath sound, localized crepitation) or radiological studies (CXR and pleural US ±CT Chest) which display compatible patterns (semihomgenous opacity with blunting of the costophrenic angle, homogenous opacity suggestive loculated effusion, air bronchogram):
- Inclusion criteria:
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyzer), low glucose level (⩽3 mole/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection .
- Failed resolution of parapneumonic effusion:
- Exclusion criteria:
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the aetiology.
- Exudative pleural effusion due to medical conditions other than pneumonia (suspected or proven Para malignant effusion, associated pulmonary embolism, autoimmune, pancreatic or esophageal disease, gynecological disorder, and drug-induced pleural effusion).
- Sample Size Calculation: The sample size was calculated using Epi-info software version 7.2.5.0 . The total sample size needed to detect such an estimate with 95% confidence level and 10% margin of error will be 95 patients. -Study tools :all patients will be subjected to:
- Demographic data (age, gender) and clinical data (including comorbidities -such as underlying COPD, D.M, HTN, cardiac, hepatic, or renal diseases, immunodeficiency or administration of immunosuppressive therapy- symptoms and their duration, time to admission, time before ICT insertion and duration of antibiotics used) will be collected and documented.
- Laboratory testing:
- Samples for baseline Complete blood count (CBC) with differential count, renal (serum urea and creatinine) and liver function tests (total protein, ALT, AST, albumin), coagulation profile (PT, PC, INR), LDH,ESR, and CRP will be , fasting and 2 hour postprandial blood sugar level will be collected, analyzed and their results will be documented.
- Biochemical and microbial analysis of the pleural effusion will be conducted. This will include pleural pH, glucose level , LDH, total protein and albumin, culture and sensitivity for bacteria, as well as direct smear for A.F.B./Gene Expert (if pleural tuberculosis is suspected) by thoracentesis using ultrasound to guide selection of an adequate length needle. At least 10 mm depth to do diagnostic thoracentesis .
- Radiological studies before and after intervention:
- Chest X ray (CXR) PA/Lateral film. ii) Contrast-enhanced CT chest if deemed necessary by the MDT. Data about extent of the effusion, presence of loculi or pleural thickening, as well as the underlying lesions (pneumonia, mass, nodules) will be documented iii) Chest US:
- The device: Curvilinear US probe (Samsung Madison CO-LTD.42 .Teheran-ro-108-gil.Gangnam-gu. Seoul. Korea) that generates a frequency range of 2-5 MHz which has great penetration but lower resolution .
- Examination protocol: Patients are to be examined in the supine and sitting positions, arms raised and hands placed at the back of the head to expand the intercostal spaces and rotate the scapula outward. Examination will be performed systematically through the intercostal spaces in six vertical lines which are mid clavicular, anterior axillary, mid axillary, posterior axillary, mid scapular and paravertebral .and will cover 8 zones in each lung side (supra-mammary, mammary ,infra-mammary, upper axillary ,lower axillary ,supra-scapular ,inter-scapular , infrascapular ) . Sonographic Findings (include fluid volume, fluid echogenicity, pleural thickening, findings demonstrating the underlying pneumonia (hyperechoic comma-shape artifacts representing air bronchogram/C profile), other incidental findings (nodules, hypoechoic lesions).
- Fluid volume: First, the maximal inter-pleural distance at posterior-lateral Alveolar and pleural syndrome (PLAPS) point is measured during expiration in a semi-recumbent position. Then, the volume of the pleural fluid will be calculated using Balik's Formula where . V(ml)= 20 x Distance (mm)
- Echogenicity: Effusion is defined as anechoic when it is echo-free, as complex non-septate when echogenic material is inside the effusion, and as complex septate when floating fibrin strands or septa are found inside the effusions.
- Assessment of Mortality and Morbidity Risks: Adjusted RAPID score is a simple and easily calculated score that assesses mortality risk for patients with pleural infections. The score entails 8 parameters (Renal (urea), age, fluid purulence, infection source, dietary (albumin), diabetes mellitus, renal insufficiency (dialysis), immunosuppression are assigned . The total adjusted RAPID score (0-10 points) represents the sum of the points assigned to the 8 parameters together, on the basis of which the patient's risk for 90 days mortality is determined .
- Assessment of Fitness for Anesthesia and Surgery: ASA score (American Society of Anesthesiologists Physical Status ) It is a standardized way to assess a patient's overall health and fitness before surgery. It uses a scale of I to VI, with I being a healthy patient and VI being a deceased organ donor. An "E" is added to the number if the procedure is an emergency. According to age, diseases severity, associated comorbidities, the anaestheology team assign the patient into one of six classes that define the patient's fitness status in a descending rank.
- Anesthesia: The type of the anesthesia that will be administrated to the patient (general or regional) will be documented, as well as the drugs used during anesthesia as (inhalational anesthetics like sevoflurane, and intravenous agents like Propofol and remifentanil). 7- VATS technique:
- Materials : The following equipment is used to perform a VATS: 1-5 or 10 mm high-resolution fiber-optic thoracoscopy with a 0° or 30° lens 2-A light source with a cable 3-Video monitors 4-Thoracoscopic instruments (scissors, hook or straight-blade cautery, biopsy forceps, grasper, and dissector) 5-Endoscopic stapler if resection is planned 6-Trocars 7-Thoracotomy tray (to convert to open procedure if needed) 8-Chest tubes and drainage devices 9-Sterile gloves, gowns, and drapes 10-Double-lumen endotracheal tube
- Procedure steps :
- The whole series will be operated upon under general anesthesia, using a double-lumen tube for selective ventilation.
- Patients will be placed in a decubitus position on an operating table with a standby set of thoracotomy instruments ready in case of conversion.
- A small incision (3-5 cm) is to be made in the 5th intercostal space anterior axillary line then dissection of the subcutaneous tissue and muscles was done. Port inserted with A 30-degree lens (Karl-Storz) in a 10-mm sheath thoracoscopy was introduced at the top of the incision.
- After opening the port site, a gentle digital palpation to push the lung away from chest wall and create a space where camera can be introduced. Using the suction tip or a sponge on a stick afterward to further continue the dissection under vision .
- Debridement technique : The aim of debridement (removal of pus, debris, granulation tissue) is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations. Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion.
- Decortication technique :
- For cases with lung entrapment by thick visceral peel or clotted hemothorax, irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura.
- A long thoracoscopy instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniport procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.
- After performing decortication, a warmed saline solution for flushing again inside the chest cavity through a 50-cc syringe for irrigation then suctioned after anesthetist start to ventilate this side and air leak was checked. -Decortication will be considered completed when near full lung expansion takes place with anesthetist inflating the lung with pressure between 30 and 35 mmHg. Failure to get the whole lung inflation needs a revision of the decortication and either continuing VATS or converting to open surgery depending on the comfort of the operator. 8-Post-Operative Care:
- ICT insertion :
- Tools: 2 hemostats, nylon suture (0 or 0-1), scalpel size (11blade), suction apparatus, water seal drainage, chest tube ranges from 28-32 French for Para pneumonic effusion.
- Chest tube will be inserted from the same port site then secured by sutures and other ports closed in standard fashion, so termination the surgical procedure and start recovery from anesthesia.
- Recovery from anesthesia: Awaken a patient after general anesthesia by gradually reduce and eventually stop the anesthetic medications. The patient will then be monitored closely as they naturally wake up and regain consciousness, breathing on their own.
- Site of admission: All Patients will be sent to the ward or the intermediate care unit, as a part of the institution's protocol.
- Analgesia: According to pain ladder score : The original ladder mainly consisted of three steps: 1-First Step: Mild pain: non-opioid analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen with or without adjuvants. 2-Second Step: Moderate pain: weak opioids (hydrocodone, codeine, tramadol) with or without non-opioid analgesics and with or without adjuvants. 3-Third Step: Severe and persistent pain: potent opioids (morphine, methadone, fentanyl, oxycodone, buprenorphine, tapentadol, hydromorphone, oxymorphone) with or without non-opioid analgesics, and with or without adjuvant. Adjuvants, also called co-analgesics, include antidepressants, including tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine, anticonvulsants like gabapentin and pregabalin, topical anesthetics (e.g., lidocaine patch), topical therapies (e.g., capsaicin), corticosteroids, bisphosphonates, and cannabinoids .
- Early mobilization and physiotherapy will be encouraged in all patients until discharge. 9-Follow Up protocol postoperative: i) Amount of drained fluid daily in cc, color (serous, pus, blood or serosanguinous) (pre-operative and post-operative). ii) CXR and Chest US in day prior to surgery and 1 day postoperative then at discharge :
- Chest X-ray is to be scored into: No change in the first X-ray before VATS takes score ( 0) Less than 1/3 improvement/lung expansion takes score(1). Improvement between 1/3 and 2/3 takes score (2). More than 2/3 improvement without complete clearance of effusion takes score(3). Complete radiological clearance/complete lung expansion takes score(4)
- Chest US findings is to be scored into: No change takes score(0). Dissolution of adhesions in some regions takes score(1). Dissolution of adhesions in all regions with residual pleural affection takes score(2). Total adhesion dissolution without residual pleural lesion takes score(3). iii) Presence of air leak at discharge. iv) Visual analogue Sore (VAS): It is a scale from 0-10 cm with 0 value on the left side representing maximum comfort and 10 representing maximum discomfort on the right side will be assessed at in day prior to surgery and 1 day postoperative then at discharge . -Research outcome measures:
<!-- -->
- Primary (main):
- Number of the patients who will receive either VATS technique (and the respective percentage in relation to the total patients)
- Preoperative Adjusted RAPID score and US findings (fluid volume, echogenicity, pleural thickening, consolidation and other incidental findings).
- Assessment the radiological signs of lung expansion: CXR/US scores: -Failure: Chest X-ray scoring 0 and chest US scoring 0.
- Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1.
- Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
- Secondary (subsidiary):
- Time to ICT removal (days): ICT tube will be removed based on the MDT joint decision according to the patients' individual course. Tube removal is contemplated upon clinical resolution, complete fluid drainage, full lung expansion and absence of pleural air in CXR, in the absence of air leak, chest ultrasound to assess if there is residual pleural effusion.
- Length of Hospital Stay (days)
- Status at discharge (ICT removed or not)
- Patients reported outcomes:
- Postoperative pain (VAS) at discharge time
- Mobility (bed bound- need for assistance as wheelchair or help of relatives to move -freely and independently ambulatory) by attending the patient to the hospital within 30 days post discharge.
- Resumption of usual activities (self-care routine with assistance - unassisted self-care- other activities indoors- independent indoors and outdoors activities) by attending the patient to the hospital within 30 days post discharge.
- Mortality rate within 30 days postoperative, documentation of the cause of death will be attempted.
- Complication : minor as bleeding, wound infection, surgical emphysema, postoperative blood transfusion or major as worsening of pneumonia, sepsis, persistent air leak, need to re-exploration.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients with complicated pleural infections, who don't improve after antibiotics and drainage of fluid by chest tube, will undergo surgery. The procedure may be debridement, where the surgeon only removes pus and debris, wash the thoracic cavity with saline and inserts chest tube. If the surgeon finds it necessary, he will proceed to decortication, where he also peels-off the thick infected pleura covering the lung to allow lung regain its size and help improvement. Follow up will include, clinical assessment, laboratory tests, periodic CXR to decide whether it's appropriate to remove the chest tube or not
| Arm | Type | Receives |
|---|---|---|
| decortication arm | Active comparator | Procedure: VATs decorticationpatients with PPE complicated by stage 3 empyema will underwent decortication technique |
| debridement arm | Active comparator | Procedure: VATs debridementpatients with PPE complicated by stage 2 empyema will underwent debridment technique |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age > 18 years
- Patients diagnosed with PPE who are confirmed by (aspiration of frank pus from pleural cavity, positive culture for bacterial infection, pleural fluid with a pH ⩽7.2 (measured by blood gas analyser), low glucose level (⩽3 mmol/L or ⩽55 mg•dL-1), lactate dehydrogenase (LDH) >200 IU/L) in a patient with clinical evidence of infection [6].
- Failed resolution of parapneumonic effusion:
- Given a patient-to-patient variability in response to medical treatment, therapeutic pleurocentesis and ICT drainage, a MDT involving consultant cardiothoracic surgeons and consultant pulmonologist are to discuss enrolled cases individually , reach consensus, and declare failure of medical treatment or ICT drainage and need for surgical intervention , based on combination of clinical , laboratory, and radiological parameters (persistence of fever. Elevated Wbcs, respiratory symptoms, pleural fluid loculi inaccessible by ICT, lung entrapment despite complete drainage of fluid or large bronchopleural fistula
Key exclusion criteria (4 listed)
- Patients unfit for/ or declining surgical intervention.
- Iatrogenic or traumatic pyothorax.
- Haemothorax or chylothorax regardless the aetiology.
- Exudative pleural effusion due to medical conditions other than pneumonia (suspected or proven Para malignant effusion, associated pulmonary embolism, autoimmune, pancreatic or oesophageal disease, gynaecological disorder, and drug-induced pleural effusion).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VATs decorticationA long thoracoscopic instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniportal procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other. Irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura. | Procedure or surgery | decortication arm |
| VATs debridementRemoval of pus, debris, granulation tissue is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations. Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion | Procedure or surgery | debridement arm |
Primary outcome
Assessment the radiological signs of lung expansion
Time frame: perioperative
CXR/US scores: * Failure: Chest X-ray scoring 0 and chest US scoring 0. * Partially successful: Chest X-ray scoring 1 or 2 and chest US scoring 1. * Successful: Chest X-ray scoring 3 or 4, and chest US scoring 2 or 3.
Preoperative Adjusted RAPID score and US findings
Time frame: the baseline
Preoperative Adjusted RAPID score which determine what is the technique will be used ( decortication or debridement ) as shown : Adjusted RAPID score is a simple and easily calculated score that assesses mortality risk for patients with pleural infections. The score entails 8 parameters (Renal (urea), age, fluid purulence, infection source, dietary (albumin), diabetes mellitus, renal insufficiency (dialysis), immunosuppression are assigned as seen in Figure(1). The total adjusted RAPID score (0-10 points) represents the sum of the points assigned to the 8 parameters together, on the basis of which the patient's risk for 90 days mortality is determined . Risk categories : score 0-2 low risk score 3-4 intermediate risk score 5-7 high risk score 8-10 very high risk
1 secondary outcome
Time to ICT removal (days)
Time frame: through study completion, an average of 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2025.
- Results publication: PubMed 18635562Bernstein WK, Deshpande S. Preoperative evaluation for thoracic surgery. Semin Cardiothorac Vasc Anesth. 2008 Jun;12(2):109-21. doi: 10.1177/1089253208319868.
- Results publication: PubMed 20439299Chambers A, Routledge T, Dunning J, Scarci M. Is video-assisted thoracoscopic surgical decortication superior to open surgery in the management of adults with primary empyema? Interact Cardiovasc Thorac Surg. 2010 Aug;11(2):171-7. doi: 10.1510/icvts.2010.240408. Epub 2010 May 3.
- Results publication: PubMed 33198004Towe CW, Carr SR, Donahue JM, Burrows WM, Perry Y, Kim S, Kosinski A, Linden PA. Morbidity and 30-day mortality after decortication for parapneumonic empyema and pleural effusion among patients in the Society of Thoracic Surgeons' General Thoracic Surgery Database. J Thorac Cardiovasc Surg. 2019 Mar;157(3):1288-1297.e4. doi: 10.1016/j.jtcvs.2018.10.157. Epub 2018 Nov 28.
- Results publication: PubMed 26836918Dean NC, Griffith PP, Sorensen JS, McCauley L, Jones BE, Lee YC. Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia. Chest. 2016 Jun;149(6):1509-15. doi: 10.1016/j.chest.2015.12.027. Epub 2016 Jan 16.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sara Mohamed Hashem, MD study chair
Assiut Medical School
Hend Mohamed Sayed, MD study chair
Assiut Medical School
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VATs decortication and VATs debridement in people with Parapneumonic Effussion, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olfat Mostafa El Shinawy, MD (020 01211194877, dr_olfat_mostafa@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment the radiological signs of lung expansion (time frame: perioperative). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07188714, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2025.